(Q44304230)

English

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis (English)

1 reference

Europe PubMed Central

1 December 2017

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

1 December 2017

Alessandra Ferrajoli

9

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

1 December 2017

Srdan Verstovsek

10

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

1 December 2017

William G Wierda

8

object named as

William G Wierda

1 reference

Europe PubMed Central

1 December 2017

2

object named as

Susan O'Brien

1 reference

Europe PubMed Central

1 December 2017

6

object named as

Mary Beth Rios

1 reference

Europe PubMed Central

1 December 2017

Jorge Eduardo Cortes

3

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

1 December 2017

Michael J. Keating

11

object named as

Michael J Keating

1 reference

Europe PubMed Central

1 December 2017

Francis J Giles

5

object named as

Francis J Giles

1 reference

Europe PubMed Central

1 December 2017

4

object named as

Jianqin Shan

1 reference

Europe PubMed Central

1 December 2017

13

object named as

Moshe Talpaz

1 reference

Europe PubMed Central

1 December 2017

author name string

Stefan H Faderl

7

1 reference

Europe PubMed Central

1 December 2017

Emil J Freireich

12

1 reference

Europe PubMed Central

1 December 2017

language of work or name

0 references

publication date

1 February 2003

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

97

1 reference

Europe PubMed Central

1 December 2017

1033-1041

1 reference

Europe PubMed Central

1 December 2017

4

1 reference

Europe PubMed Central

1 December 2017

Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11223

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11223

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44304230&oldid=2109307863"